Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023–2038.
   Google Scholar
• Das S, Padhan P. An overview of the extraarticular involvement in rheumatoid arthritis and its management. J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):81–86.
   Google Scholar
• Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001 May;27(2):269–281.
   Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205–2219.
   Google Scholar
• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. Jama. 2018 Oct 2;320(13):1360–1372.
   Google Scholar
• Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008 Jun;223:7–19.
   Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010 Sep 25;376(9746):1094–1108.
   Google Scholar
• Finckh A, Liang MH, van Herckenrode CM, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006 Dec 15;55(6):864–872.
   Google Scholar
• Kyburz D, Gabay C, Michel BA, et al. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford). 2011 Jun;50(6):1106–1110.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569–2581.
   Google Scholar
• Chen SJ, Lin GJ, Chen JW, et al. Immunopathogenic mechanisms and novel immune-modulated therapies in rheumatoid arthritis. Int J Mol Sci. 2019 Mar 16;20(6):1332.
   Google Scholar
• Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res. 2019;8:F1000 Faculty Rev–1549.
   Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
   Google Scholar
• Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017 Jun 10;389(10086):2338–2348.
   Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar;70(3):404–413.
   Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013 Feb 7;121(6):898–904.
   Google Scholar
• Rajitha P, Biswas R, Sabitha M, et al. Methotrexate in the treatment of psoriasis and rheumatoid arthritis: mechanistic insights, current issues and novel delivery approaches. Curr Pharm Des. 2017;23(24):3550–3566.
   Google Scholar
• Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951 Feb;221(2):176–182.
   Google Scholar
• Malaviya AN. Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. Int J Rheum Dis. 2016 Sep;19(9):844–851.
   Google Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016 Dec;12(12):731–742.
   Google Scholar
• Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004 Mar;43(3):267–271.
   Google Scholar
• Vincenzi F, Padovan M, Targa M, et al. A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. PLoS One. 2013;8(1):e54195.
   Google Scholar
• Bar-Yehuda S, Silverman MH, Kerns WD, et al. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs. 2007 Oct;16(10):1601–1613.
   Google Scholar
• Teramachi J, Kukita A, Li YJ, et al. Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. Lab Invest. 2011 May;91(5):719–731.
   Google Scholar
• Sigmundsdottir H, Johnston A, Gudjonsson JE, et al. Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol. 2004 Jul;13(7):426–434.
   Google Scholar
• Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005 Feb 1;114(2):154–163.
   Google Scholar
• Dolhain RJ, Tak PP, Dijkmans BA, et al. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol. 1998 May;37(5):502–508.
   Google Scholar
• Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res. 2005 Jul;54(7):273–280.
   Google Scholar
• Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol. 2003 Feb;138(3):501–511.
   Google Scholar
• Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis-a review. Br J Clin Pharmacol. 2019 Oct;85(10):2228–2234.
   Google Scholar
• Sparks JA, Barbhaiya M, Karlson EW, et al. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: rationale and design of the cardiovascular inflammation reduction trial-adverse events (CIRT-AE) study. Semin Arthritis Rheum. 2017 Aug;47(1):133–142.
   Google Scholar
• Qiu Q, Huang J, Lin Y, et al. Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic review and meta-analysis. Medicine (Baltimore). 2017 Mar;96(11):e6337.
   Google Scholar
• Qiu Q, Huang J, Shu X, et al. Polymorphisms and pharmacogenomics for the clinical efficacy of methotrexate in patients with rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep. 2017 Mar;7(7):44015.
   Google Scholar
• Ross JS, Schenkein DP, Kashala O, et al. Pharmacogenomics. Adv Anat Pathol. 2004 Jul;11(4):211–220.
   Google Scholar
• Tarnowski M, Paradowska-Gorycka A, Dabrowska-Zamojcin E, et al. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. Expert Opin Drug Metab Toxicol. 2016;12(1):41–55.
   Google Scholar
• Kooloos WM, Huizinga TW, Guchelaar HJ, et al. Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des. 2010;16(2):164–175.
   Google Scholar
• Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics. 2013 Feb;14(3):305–314.
   Google Scholar
• Zhu H, Deng FY, Mo XB, et al. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics. 2014 Mar;15(4):551–566.
   Google Scholar
• Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12–19.
   Google Scholar
• Machaj F, Rosik J, Szostak B, et al. The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. Expert Opin Drug Discov. 2020;15(1):85–99.
   Google Scholar
• Lima A, Bernardes M, Azevedo R, et al. Moving toward personalized medicine in rheumatoid arthritis: sNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics. 2016 Oct;17(15):1649–1674.
   Google Scholar
• Wessels JA, Kooloos WM, De Jonge R, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006 Sep;54(9):2830–2839.
   Google Scholar
• Lee YC, Cui J, Costenbader KH, et al. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford). 2009 Jun;48(6):613–617.
   Google Scholar
• Swierkot J, Bogunia-Kubik K, Nowak B, et al. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint Bone Spine. 2015 Mar;82(2):94–99.
   Google Scholar
• James HM, Gillis D, Hissaria P, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):562–571.
   Google Scholar
• Drozdzik M, Rudas T, Pawlik A, et al. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 2007 Dec;7(6):404–407.
   Google Scholar
• Szekanecz Z, Meskó B, Poliska S, et al. Pharmacogenetics and pharmacogenomics in rheumatology. Immunol Res. 2013 Jul;56(2–3):325–333.
   Google Scholar
• Zhang LL, Yang S, Wei W, et al. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis. Pharmacogenet Genomics. 2014 Nov;24(11):531–538.
   Google Scholar
• Kodidela S, Pradhan S, Dubashi B. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level? Eur J Clin Pharmacol. 2013;70(3):253–260.
   Google Scholar
• Ando Y, Shimada H, Matsumoto N, et al. Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes. Drug Metab Pharmacokinet. 2013;28(5):442–445.
   Google Scholar
• Hayashi H, Fujimaki C, Daimon T, et al. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther. 2009 Jun;34(3):355–361.
   Google Scholar
• Hayashi H, Tazoe Y, Tsuboi S, et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2013;28(2):164–168.
   Google Scholar
• Bohanec Grabar P, Leandro-Garcia LJ, Inglada-Perez L, et al. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients. Pharmacogenomics. 2012 Nov;13(14):1583–1594.
   Google Scholar
• Lima A, Bernardes M, Sousa H, et al. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics. 2014 Apr;15(6):807–820.
   Google Scholar
• Lima A, Bernardes M, Azevedo R, et al. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196–209.
   Google Scholar
• Takatori R, Takahashi KA, Tokunaga D, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006 Sep-Oct;24(5):546–554.
   Google Scholar
• Wessels JA, de Vries-bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006 Apr;54(4):1087–1095.
   Google Scholar
• Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007 Aug;127(8):1860–1867.
   Google Scholar
• Kung TN, Dennis J, Ma Y, et al. RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. Arthritis Rheumatol. 2014 May;66(5):1111–1120.
   Google Scholar
• Li X, Hu M, Li W, et al. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis. Int Immunopharmacol. 2016 Sep;38:8–15.
   Google Scholar
• Lee YH, Bae SC, Song GG. Association of the ABCB1 C3435T polymorphism with responsivenessto and toxicity of DMARDs in rheumatoid arthritis. Z Rheumatol. 2016 Sep;75(7):707–715.
   Google Scholar
• Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab. 2009 Jul;10(6):547–566.
   Google Scholar
• Davila-Fajardo CL, Swen JJ, Cabeza Barrera J, et al. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics. 2013 Jan;14(1):63–73.
   Google Scholar
• Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics. 2011 Oct;12(10):1449–1463.
   Google Scholar
• Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54(10):3095–3103.
   Google Scholar
• Kurzawski M, Pawlik A, Safranow K, et al. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics. 2007 Nov;8(11):1551–1559.
   Google Scholar
• Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May 1;10(1):111–113.
   Google Scholar
• Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig. 2010;30(2):101–108.
   Google Scholar
• Spyridopoulou KP, Dimou NL, Hamodrakas SJ, et al. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics. 2012 Feb;22(2):117–133.
   Google Scholar
• Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol. 2009 Mar;36(3):539–545.
   Google Scholar
• Song GG, Bae SC, Lee YH. Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2014 Dec;33(12):1715–1724.
   Google Scholar
• Huang L, Tissing WJE, de Jonge R, et al. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22(9):1798–1800.
   Google Scholar
• Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumor Biol. 2012;33(5):1445–1454.
   Google Scholar
• Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94(10):1391–1398.
   Google Scholar
• Lima A, Seabra V, Bernardes M, et al. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients. PloS One. 2014;9(10):e108165–e108165.
   Google Scholar
• Owen SA, Hider SL, Martin P, et al. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 2013 Jun;13(3):227–234.
   Google Scholar
• Lee YH, Bae SC. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2016 Nov;36(11):1591–1599.
   Google Scholar
• Korte A, Farlow A. The advantages and limitations of trait analysis with GWAS: a review. Plant Methods. 2013;9:29.
   Google Scholar
• Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am J Hum Genet. 2010 Jan;86(1):6–22.
   Google Scholar
• Lopez-Rodriguez R, Ferreiro-Iglesias A, Lima A, et al. Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May 9;8(1):7342.
   Google Scholar
• Taylor JC, Bongartz T, Massey J, et al. Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics J. 2018 Jul;18(4):528–538.
   Google Scholar
• Bluett J, Owen SA, Massey J, et al. HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. Ann Rheum Dis. 2017 Dec;76(12):e51.
   Google Scholar
• Cobb J, Cule E, Moncrieffe H, et al. Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharmacogenomics J. 2014;14(4):356–364.
   Google Scholar
• Senapati S, Singh S, Das M, et al. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet Genomics. 2014;24(4):211–219.
   Google Scholar
• Furukawa H, Oka S, Shimada K, et al. HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis. 2013 Jan;72(1):153–155.
   Google Scholar
• Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res. 2004 May 1;62(2):228–232.
   Google Scholar
• Grundberg E, Small KS, Hedman AK, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet. 2012 Oct;44(10):1084–1089.
   Google Scholar
• Koval M, Billaud M, Straub AC, et al. Spontaneous lung dysfunction and fibrosis in mice lacking connexin 40 and endothelial cell connexin 43. Am J Pathol. 2011 Jun;178(6):2536–2546.
   Google Scholar
• Acosta-Herrera M, Kerick M, González-Serna D, et al. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. Ann Rheum Dis. 2019;78(3):311.
   Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. Sabaté E, edited by. Geneva: World Health Organization; 2003.
   Google Scholar